Free Trial Information
BioCentury | Jan 15, 2015
Finance

Consortia cross-talk

...acids to treat cancers resistant to radio/chemotherapy (TEDAC) Erytech Pharma S.A. (Euronext:ERYP); ExonHit S.A. (Euronext:ALEHT); InGen BioSciences Group...
Read More
BioCentury | May 27, 2013
Finance

Demand disequilibrium

...business. Ark Therapeutics Group plc is now a manufacturing services provider; ExonHit S.A. acquired diagnostics InGen Biosciences Group...
Read More
BioCentury | Dec 24, 2012
Company News

ExonHit, InGen BioSciences deal

...on Euronext under the symbol "ALEHT" (see BioCentury, Nov. 12). ExonHit S.A. (Euronext:ALEHT), Paris, France InGen Biosciences Group...
Read More
BioCentury | Nov 12, 2012
Company News

ExonHit, InGen BioSciences deal

...to ExonHit shareholder approval, is expected to close Dec. 19. ExonHit S.A. (Euronext:ALEHT), Paris, France InGen Biosciences Group...
Read More
BioCentury | Jun 11, 2012
Company News

ExonHit, OSEO cancer news

...$13 million) in funding. The consortium is led by Erytech Pharma (Lyon, France) and includes InGen BioSciences Group...
Read More
BioCentury | Jan 3, 2011
Company News

Ingen Biosciences management update

Ingen Biosciences Group , Chilly-Mazarin, France Business: Diagnostic Hired: Isabelle Buckle as CEO, formerly worldwide business director for global strategic accounts at Applied Biosystems Group , which merged with Invitrogen Corp. to form Life Technologies Corp. WIR...
Read More
BioCentury | Jul 19, 2010
Company News

Ingen Biosciences management update

Ingen Biosciences Group , Chilly-Mazarin, France Business: Diagnostic Hired: Karine Mignon-Godefroy as director of R&D, formerly director of international projects at the blood virus division of Bio-Rad Laboratories Inc. WIR Staff Diagnostic...
Read More
Items per page:
1 - 7 of 7
BioCentury | Jan 15, 2015
Finance

Consortia cross-talk

...acids to treat cancers resistant to radio/chemotherapy (TEDAC) Erytech Pharma S.A. (Euronext:ERYP); ExonHit S.A. (Euronext:ALEHT); InGen BioSciences Group...
Read More
BioCentury | May 27, 2013
Finance

Demand disequilibrium

...business. Ark Therapeutics Group plc is now a manufacturing services provider; ExonHit S.A. acquired diagnostics InGen Biosciences Group...
Read More
BioCentury | Dec 24, 2012
Company News

ExonHit, InGen BioSciences deal

...on Euronext under the symbol "ALEHT" (see BioCentury, Nov. 12). ExonHit S.A. (Euronext:ALEHT), Paris, France InGen Biosciences Group...
Read More
BioCentury | Nov 12, 2012
Company News

ExonHit, InGen BioSciences deal

...to ExonHit shareholder approval, is expected to close Dec. 19. ExonHit S.A. (Euronext:ALEHT), Paris, France InGen Biosciences Group...
Read More
BioCentury | Jun 11, 2012
Company News

ExonHit, OSEO cancer news

...$13 million) in funding. The consortium is led by Erytech Pharma (Lyon, France) and includes InGen BioSciences Group...
Read More
BioCentury | Jan 3, 2011
Company News

Ingen Biosciences management update

Ingen Biosciences Group , Chilly-Mazarin, France Business: Diagnostic Hired: Isabelle Buckle as CEO, formerly worldwide business director for global strategic accounts at Applied Biosystems Group , which merged with Invitrogen Corp. to form Life Technologies Corp. WIR...
Read More
BioCentury | Jul 19, 2010
Company News

Ingen Biosciences management update

Ingen Biosciences Group , Chilly-Mazarin, France Business: Diagnostic Hired: Karine Mignon-Godefroy as director of R&D, formerly director of international projects at the blood virus division of Bio-Rad Laboratories Inc. WIR Staff Diagnostic...
Read More
Items per page:
1 - 7 of 7